// App-Quantinova.ai

232 : Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated ?-fetoprotein (AFP) from the randomized phase III REACH study.

Researchers

Presenter

  • Andrew X. Zhu

Principal Investigators

  • Chia-Jui Yen

  • Katerina Kubackova

  • Jorg Trojan

  • Javier Sastre

  • Ian Chau

  • Shao-Chun Chang

  • Paolo Abada

  • Ling Yang

  • Yanzhi Hsu

  • Davide Pastorelli

  • Jean-Frederic Blanc

  • Hyun Cheol Chung

  • Ari David Baron

  • Tulio Eduardo Flesch Pfiffer

  • Takuji Okusaka

  • Joon Oh Park

  • Masatoshi Kudo

  • Ronnie Tung-Ping Poon

Medical Centers

  • Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Japan

  • Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan

  • U.O. Oncologia Medica 2, Istituto Oncologico Veneto - IRCCS, Padova, Italy

  • Johann Wolfgang Goethe-University, Frankfurt, Germany.

  • Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, Brazil

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Pacific Hematology Oncology Associates, San Francisco, CA

  • Eli Lilly and Company, Bridgewater, NJ

  • Samsung Medical Center, Sungkyunkwan University, Seoul, South KoreaQueen Mary Hospital, Hong Kong, ChinaEli Lilly and Company, Indianapolis, IN

  • Hopital Saint-Andre, Bordeaux, France

  • Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan

  • Department of Oncology, University Hospital of Motol, Charles University, Prague, Czech Republic

  • Massachusetts General Hospital Cancer Center, Boston, MA

Locations

  • Brazil

  • Czech Republic

  • Taiwan

  • Japan

  • Italy

  • Germany

  • Spain

  • United Kingdom

  • United States

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

Biomarkers

  • Alpha-fetoprotein

Drug/Treatment

  • Ramucirumab

Outcome

  • N/A

Study Design

  • randomized

Phase

  • III

Study Id's

  • NCT01140347

Sponsors

  • Eli Lilly and Company

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved